ReXceptor looking to raise funding for phase I #clinicaltrial

ReXceptor look to fund clinical trials Neuroscientists from Case Western Reserve University made a breakthrough earlier this year when they found the FDA approved cancer drug Bexarotene also appears to reverse the pathological, cognitive & memory deficits of Alzheimers in mice.

The researchers have now formed a company, ReXceptor, and are looking to raise funding for a phase I clinical trial. The jump from mice to humans is one of the most difficult steps in drug development but the results could be amazing!

Leave a Reply

Your email address will not be published. Required fields are marked *